CY1122475T1 - Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης - Google Patents

Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης

Info

Publication number
CY1122475T1
CY1122475T1 CY20191101316T CY191101316T CY1122475T1 CY 1122475 T1 CY1122475 T1 CY 1122475T1 CY 20191101316 T CY20191101316 T CY 20191101316T CY 191101316 T CY191101316 T CY 191101316T CY 1122475 T1 CY1122475 T1 CY 1122475T1
Authority
CY
Cyprus
Prior art keywords
polymeric material
core
outer layer
layer
drug
Prior art date
Application number
CY20191101316T
Other languages
English (en)
Inventor
Thomas Buser
Frédéric Jean-Claude Goutte
Abdul Waseh Basit
Felipe José Oliveria Varum
Ana Cristina Freire
Roberto Carlos Bravo Gonzàles
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46025554&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122475(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of CY1122475T1 publication Critical patent/CY1122475T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Laminated Bodies (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Grain Derivatives (AREA)

Abstract

Καθυστερημένη έκλυση ενός φαρμάκου στο κόλον επιτυγχάνεται από μια μορφοποίηση καθυστερημένης έκλυσης που περιλαμβάνει έναν πυρήνα και μια επικάλυψη για τον πυρήνα. Ο πυρήνας περιλαμβάνει ένα φάρμακο και η επικάλυψη περιλαμβάνει μια εξωτερική στοιβάδα και μια τουλάχιστον στοιβάδα ανάμεσα στον πυρήνα και την εξωτερική στοιβάδα η οποία επιλέγεται από την ομάδα που αποτελείται από μια μονωτική στοιβάδα και μια εσωτερική στοιβάδα. Η εξωτερική στοιβάδα περιλαμβάνει ένα μείγμα από ένα πρώτο πολυμερές υλικό, το οποίο είναι ευαίσθητο σε επίθεση από βακτήρια του κόλου, και ένα δεύτερο πολυμερές υλικό, το οποίο έχει κατώφλι pΗ περίπου 6 ή μεγαλύτερο. Η εσωτερική στοιβάδα περιλαμβάνει ένα τρίτο πολυμερές το οποίο είναι ένα μη ιονικό πολυμερές που είναι διαλυτό στο εντερικό υγρό ή στο γαστρεντερικό υγρό. Η εξωτερική στοιβάδα εφαρμόζει απευθείας στην εσωτερική στοιβάδα ή στη μονωτική στοιβάδα με τη χρήση ενός παρασκευάσματος επικάλυψης που σχηματίζεται μέσω του συνδυασμού του πρώτου πολυμερούς υλικού σε ένα υδατικό μέσο με ένα δεύτερο πολυμερές υλικό σε ένα οργανικό μέσο. Πλεονεκτήματα των μορφοποιήσεων σύμφωνα με την παρούσα εφεύρεση περιλαμβάνουν επιταχυνόμενη έκλυση του φαρμάκου όταν εκτίθεται σε συνθήκες του κόλου και μείωση ή εξάλειψη μιας επίδρασης τροφής ή/και αλκοόλης στην έκλυση του φαρμάκου μετά από τη χορήγηση.
CY20191101316T 2012-04-30 2019-12-16 Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης CY1122475T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261640217P 2012-04-30 2012-04-30
EP12166110.2A EP2659881B1 (en) 2012-04-30 2012-04-30 A delayed release drug formulation
PCT/EP2013/058923 WO2013164316A1 (en) 2012-04-30 2013-04-29 A delayed release drug formulation
EP13723033.0A EP2844222B1 (en) 2012-04-30 2013-04-29 A delayed release drug formulation

Publications (1)

Publication Number Publication Date
CY1122475T1 true CY1122475T1 (el) 2021-01-27

Family

ID=46025554

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20181100237T CY1120215T1 (el) 2012-04-30 2018-02-27 Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης
CY20181100815T CY1120492T1 (el) 2012-04-30 2018-08-06 Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης
CY20191100417T CY1121609T1 (el) 2012-04-30 2019-04-16 Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης
CY20191101316T CY1122475T1 (el) 2012-04-30 2019-12-16 Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CY20181100237T CY1120215T1 (el) 2012-04-30 2018-02-27 Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης
CY20181100815T CY1120492T1 (el) 2012-04-30 2018-08-06 Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης
CY20191100417T CY1121609T1 (el) 2012-04-30 2019-04-16 Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης

Country Status (40)

Country Link
US (6) US9364440B2 (el)
EP (6) EP3187171A1 (el)
JP (2) JP6621661B2 (el)
KR (6) KR102198621B1 (el)
CN (5) CN110200949B (el)
AR (1) AR090898A1 (el)
AU (4) AU2013255914B2 (el)
BR (3) BR122019022551B1 (el)
CA (4) CA2871017A1 (el)
CL (2) CL2014002796A1 (el)
CO (2) CO7151506A2 (el)
CR (4) CR20190245A (el)
CU (1) CU24304B1 (el)
CY (4) CY1120215T1 (el)
DK (5) DK2659881T3 (el)
EA (2) EA032514B1 (el)
ES (5) ES2655622T3 (el)
GE (4) GEP201706753B (el)
HR (2) HRP20180068T1 (el)
HU (5) HUE036187T2 (el)
JO (6) JOP20200144A1 (el)
LT (5) LT2659881T (el)
ME (2) ME03641B (el)
MX (3) MX366677B (el)
MY (3) MY169161A (el)
NO (1) NO2659881T3 (el)
NZ (3) NZ725409A (el)
PE (3) PE20150129A1 (el)
PH (2) PH12014502340B1 (el)
PL (5) PL2659881T3 (el)
PT (5) PT2659881T (el)
RS (5) RS56839B1 (el)
SA (2) SA115370043B1 (el)
SG (2) SG11201406798WA (el)
SI (5) SI2659881T1 (el)
TN (2) TN2014000442A1 (el)
TR (3) TR201903569T4 (el)
TW (3) TWI705833B (el)
UY (1) UY34772A (el)
WO (2) WO2013164316A1 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24342B1 (es) * 2012-04-30 2018-05-08 Tillotts Pharma Ag Formulación de fármaco de liberación retardada
EP3187171A1 (en) * 2012-04-30 2017-07-05 Tillotts Pharma AG A delayed release drug formulation
US20140141075A1 (en) * 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
US20150374632A1 (en) * 2013-02-22 2015-12-31 Zeria Pharmaceutical Co., Ltd. Enteric coated tablet
BR112016004863B1 (pt) 2013-10-29 2022-09-20 Tillotts Pharma Ag Formulação de droga de liberação retardada
ES2818073T3 (es) 2013-12-24 2021-04-09 Sentiss Pharma Private Ltd Solución oftálmica de tartrato de brimonidina tópica
US10945974B2 (en) 2015-06-01 2021-03-16 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
ES2930848T3 (es) 2015-09-23 2022-12-22 Xwpharma Ltd Profármacos de ácido gamma-hidroxibutírico, composiciones y usos de los mismos
CN105816883B (zh) * 2016-02-03 2018-12-14 华南师范大学 一种负载抗癌药物姜黄素的益生菌叶酸靶向载体及其制备方法
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
AU2017368074A1 (en) * 2016-11-30 2019-06-13 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
WO2019183208A1 (en) * 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
BR112020019128A2 (pt) * 2018-03-23 2021-01-12 Palatin Technologies, Inc. Formulação farmacêutica de liberação em trato gastrointestinal inferior; formulação farmacêutica de liberação no trato gastrointestinal inferior preparada por um processo; processo; formulação de liberação modificada; composição farmacêutica adequada para administração oral para tratamento de uma doença inflamatória intestinal; e método de tratamento de doença inflamatória intestinal (ibd) em um paciente humano com ibd
EP3883634A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3662902B1 (en) 2018-12-07 2024-07-31 Tillotts Pharma AG Colonic drug delivery formulation
EP3662901A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
HUE057346T2 (hu) * 2018-12-10 2022-05-28 Aphaia Ip Ag Orális gyógyászati adagolási forma metabolikus rendellenességek és rokon betegségek enterokinek megtervezett felszabadításával történõ kezelésére
WO2020257017A1 (en) 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
WO2021030474A1 (en) * 2019-08-12 2021-02-18 Massachusetts Institute Of Technology Articles and methods for administration of therapeutic agents
WO2021094697A1 (fr) * 2019-11-13 2021-05-20 Ethypharm Procédé de fabrication d'une composition pharmaceutique à administration orale et à délivrance colonique
FR3102931B1 (fr) * 2019-11-13 2021-12-24 Ethypharm Sa Procédé de fabrication d’une composition pharmaceutique à administration orale et à délivrance colonique
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
CN111567678A (zh) * 2020-05-11 2020-08-25 四川英格瑞生物科技有限公司 无抗畜类肠道保健剂及其制备方法
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5291419A (en) * 1976-01-28 1977-08-01 Fuji Yakuhin Kogyo Kk Coloring image forming photosensitive sheet
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
DE4217920C2 (de) * 1992-05-30 1996-05-09 Goldwell Gmbh Verfahren zur Herstellung von pulverförmigen Mitteln zum Blondieren von menschlichen Haaren
AU5376894A (en) * 1992-11-06 1994-06-08 Hisamitsu Pharmaceutical Co., Inc. Peroral pharmaceutical preparation releasable in lower digestive tract
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
CA2236605A1 (en) * 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
ATE238797T1 (de) * 1999-12-16 2003-05-15 Medinfar Produtos Farmaceutico Piroxicam enthaltende gastrointestinale zubereitung aus merheren einheiten bestehend
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780A (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US6939920B2 (en) 2001-01-08 2005-09-06 The Goodyear Tire & Rubber Company Tire sidewall compounds having improved flex fatigue and tread compound having improved tear strength
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
CN1293867C (zh) 2001-05-25 2007-01-10 爱诗爱诗制药株式会社 药物复合制剂
US7183321B2 (en) 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
JP2006515318A (ja) * 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
CN1964704A (zh) * 2004-03-03 2007-05-16 特瓦制药工业有限公司 包含酸不稳定药物的稳定药用组合物
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1904039A2 (en) 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Controlled release dosage formulation of duloxetine
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JP4984695B2 (ja) 2006-07-11 2012-07-25 株式会社明電舎 色素増感型太陽電池及びその製造方法
SK287622B6 (sk) * 2006-07-25 2011-04-05 Peter Pap Odkladacia schránka
US20090175935A1 (en) 2006-08-14 2009-07-09 Torrent Research Ltd. Pharmaceutical compositions of duloxetine
US20100055173A1 (en) * 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
US20100179170A1 (en) * 2006-12-05 2010-07-15 Lisa Claire Du Toit Heterogeneously configured multiparticulate gastrointestinal drug delivery system
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
CA2684655A1 (en) * 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. Oral pharmaceutical preparation for colon-specific delivery
SI2152250T1 (sl) * 2007-05-07 2020-06-30 Evonik Operations Gmbh Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) * 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
HUE054298T2 (hu) 2009-06-15 2021-08-30 Amarin Pharmaceuticals Ie Ltd Készítmények és módszerek stroke kezelésére egy konkomittáns sztatin terápián tartott alanyban
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
WO2011049309A2 (ko) * 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
US20130259947A1 (en) 2010-11-29 2013-10-03 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
JP2014529630A (ja) 2011-09-07 2014-11-13 ザウラー−ブロシュ、ローラント 哺乳類の消化管における一つあるいは複数の物質の放出制御製剤
CN102319218B (zh) 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
EP3187171A1 (en) 2012-04-30 2017-07-05 Tillotts Pharma AG A delayed release drug formulation
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool
BR112016004863B1 (pt) 2013-10-29 2022-09-20 Tillotts Pharma Ag Formulação de droga de liberação retardada

Also Published As

Publication number Publication date
HUE042833T2 (hu) 2019-07-29
CY1120492T1 (el) 2019-07-10
JP6621662B2 (ja) 2019-12-18
JOP20200144A1 (ar) 2017-06-16
MY169161A (en) 2019-02-19
JOP20200147B1 (ar) 2023-09-17
JOP20200148B1 (ar) 2023-09-17
AU2017210571A1 (en) 2017-08-24
PT3278792T (pt) 2019-05-23
SI3189830T1 (en) 2018-08-31
DK2659881T3 (en) 2018-02-05
SG11201406798WA (en) 2014-11-27
KR20150004911A (ko) 2015-01-13
EP2659881A1 (en) 2013-11-06
CL2014002795A1 (es) 2015-02-13
US11517534B2 (en) 2022-12-06
ES2761341T3 (es) 2020-05-19
BR112014026935A2 (pt) 2017-06-27
EP3278792B1 (en) 2019-02-20
SA113340508B1 (ar) 2016-02-07
SI2659881T1 (en) 2018-03-30
MX367127B (es) 2019-08-06
EP2844222B1 (en) 2019-11-13
PT2659881T (pt) 2018-01-29
ES2655622T3 (es) 2018-02-20
HRP20180965T1 (hr) 2018-08-10
EA032514B1 (ru) 2019-06-28
RS59697B1 (sr) 2020-01-31
US10272048B2 (en) 2019-04-30
BR122019022551B1 (pt) 2022-07-19
EA032811B1 (ru) 2019-07-31
LT3189830T (lt) 2018-07-10
CA3052460C (en) 2022-06-07
AU2017210577B2 (en) 2018-11-29
RS57431B1 (sr) 2018-09-28
MY190392A (en) 2022-04-20
CN104302274A (zh) 2015-01-21
NZ629262A (en) 2017-01-27
US20140056980A1 (en) 2014-02-27
CN104271113B (zh) 2019-03-22
KR102198621B1 (ko) 2021-01-06
PL2844220T3 (pl) 2019-06-28
KR102177773B1 (ko) 2020-11-12
US20170266117A1 (en) 2017-09-21
GEP201706753B (en) 2017-10-25
CA2871017A1 (en) 2013-11-07
PT2844220T (pt) 2019-03-27
GEP201706759B (en) 2017-10-25
JOP20200148A1 (ar) 2022-10-30
ME03364B (me) 2019-10-20
EA201491781A1 (ru) 2014-12-30
US9364440B2 (en) 2016-06-14
PL3189830T3 (pl) 2018-11-30
MX2014012888A (es) 2015-04-13
MY169088A (en) 2019-02-15
PE20150129A1 (es) 2015-02-13
HUE036187T2 (hu) 2018-06-28
US20150132380A1 (en) 2015-05-14
GEP201706736B (en) 2017-09-25
AU2013255913A1 (en) 2014-11-13
US9814681B2 (en) 2017-11-14
TWI618547B (zh) 2018-03-21
US20170035698A1 (en) 2017-02-09
RS58735B1 (sr) 2019-06-28
KR102102198B1 (ko) 2020-04-21
JOP20200146B1 (ar) 2023-09-17
SI3278792T1 (sl) 2019-06-28
MX2014012887A (es) 2015-05-08
LT2659881T (lt) 2018-02-12
EP2844220A1 (en) 2015-03-11
JOP20200147A1 (ar) 2022-10-30
PH12014502339B1 (en) 2014-12-22
TW201720430A (zh) 2017-06-16
PE20142442A1 (es) 2015-01-28
HUE043238T2 (hu) 2019-08-28
CA2871016C (en) 2023-03-21
CY1120215T1 (el) 2018-12-12
EP3187171A1 (en) 2017-07-05
DK3278792T3 (da) 2019-05-06
PT2844222T (pt) 2019-12-30
KR102104070B1 (ko) 2020-04-24
CN110237056B (zh) 2022-03-08
DK3189830T3 (en) 2018-07-16
JP2015515964A (ja) 2015-06-04
AU2017210571B2 (en) 2018-11-29
EP2844222A1 (en) 2015-03-11
SA115370043B1 (ar) 2016-05-24
PH12014502339A1 (en) 2014-12-22
ES2714448T3 (es) 2019-05-28
JOP20200145A1 (ar) 2022-10-30
LT2844222T (lt) 2019-12-27
CN110200949A (zh) 2019-09-06
LT3278792T (lt) 2019-05-10
CN110237056A (zh) 2019-09-17
TWI700102B (zh) 2020-08-01
EP3278792A1 (en) 2018-02-07
CL2014002796A1 (es) 2015-02-06
WO2013164316A1 (en) 2013-11-07
TWI705833B (zh) 2020-10-01
MX366677B (es) 2019-07-19
JOP20200145B1 (ar) 2023-09-17
CN110200949B (zh) 2021-11-16
HUE046628T2 (hu) 2020-03-30
CR20190245A (es) 2019-07-29
DK2844222T3 (da) 2019-12-09
ES2673931T3 (es) 2018-06-26
US20200214987A1 (en) 2020-07-09
EP2659881B1 (en) 2017-11-29
HRP20180068T1 (hr) 2018-03-23
NO2659881T3 (el) 2018-04-28
JO3574B1 (ar) 2020-07-05
US11534406B2 (en) 2022-12-27
TN2014000441A1 (en) 2016-03-30
CY1121609T1 (el) 2020-05-29
US20150125525A1 (en) 2015-05-07
AU2013255914A1 (en) 2014-11-13
KR20200075024A (ko) 2020-06-25
AU2013255914B2 (en) 2017-08-31
TR201903569T4 (tr) 2019-04-22
EP3189830A1 (en) 2017-07-12
CO7151506A2 (es) 2014-12-29
AR090898A1 (es) 2014-12-17
PH12014502340A1 (en) 2014-12-22
CN104271113A (zh) 2015-01-07
CR20140486A (es) 2015-01-19
BR112014026933A2 (pt) 2017-06-27
TR201809416T4 (tr) 2018-07-23
CR20140485A (es) 2015-01-19
TN2014000442A1 (en) 2016-03-30
HUE037702T2 (hu) 2018-09-28
EP3189830B1 (en) 2018-05-23
TR201905226T4 (tr) 2019-05-21
RS58625B1 (sr) 2019-05-31
CA2871016A1 (en) 2013-11-07
CR20190246A (es) 2019-09-03
JP6621661B2 (ja) 2019-12-18
CA3052460A1 (en) 2013-11-07
MX362529B (es) 2019-01-23
KR20190127984A (ko) 2019-11-13
PL2844222T3 (pl) 2020-03-31
KR20200073296A (ko) 2020-06-23
JOP20200146A1 (ar) 2022-10-30
US10226430B2 (en) 2019-03-12
CA3080035A1 (en) 2013-11-07
AU2013255913B2 (en) 2017-08-31
LT2844220T (lt) 2019-04-10
CU20140123A7 (es) 2015-02-26
PL2659881T3 (pl) 2018-05-30
ES2720258T3 (es) 2019-07-19
WO2013164315A1 (en) 2013-11-07
JP2015515965A (ja) 2015-06-04
SI2844220T1 (sl) 2019-05-31
EP2844220B1 (en) 2019-01-23
CN106983735A (zh) 2017-07-28
ME03641B (me) 2020-07-20
BR112014026933B1 (pt) 2022-07-19
EA201491783A1 (ru) 2014-12-30
TW201343202A (zh) 2013-11-01
PT3189830T (pt) 2018-10-19
PE20190625A1 (es) 2019-04-26
SI2844222T1 (sl) 2020-02-28
AU2017210577A1 (en) 2017-08-24
UY34772A (es) 2013-11-29
CU24304B1 (es) 2018-01-10
NZ725409A (en) 2018-05-25
DK2844220T3 (en) 2019-04-08
GEP201706758B (en) 2017-10-25
NZ629260A (en) 2017-01-27
TW202037370A (zh) 2020-10-16
SG11201406799XA (en) 2014-11-27
RS56839B1 (sr) 2018-04-30
PL3278792T3 (pl) 2019-09-30
PH12014502340B1 (en) 2014-12-22
KR20190127986A (ko) 2019-11-13
CO7141433A2 (es) 2014-12-12
KR20150004910A (ko) 2015-01-13

Similar Documents

Publication Publication Date Title
CY1122475T1 (el) Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης
CY1121470T1 (el) Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης
CU20140124A7 (es) Formulación de fármaco de liberación retardada